Merestinib

美瑞替尼

Report date: 2025/06/24 16:51:48
NME

Base Information

Drug NameMerestinib
Drug Alias Name美乐替尼Merestinibum美雷替尼5OGS5K699ELY-2801653
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatocyte growth factor receptor inhibitorsAXL receptor tyrosine kinase inhibitorsDiscoidin domain receptor 1 antagonists +[16] 
TargetsHepatocyte growth factor receptorAXL receptor tyrosine kinaseDiscoidin domain receptor 1 +[15] 
Therapy Area/IndicationsBone metastasesSkin MelanomaSolid tumours +[16] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[20] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly And Company
Inactive CompaniesUtah State UniversityDana-Farber Cancer Institute
Active IndicationsSkin MelanomaSolid tumoursMicrosatellite instability-high cancer +[7] 
Inactive IndicationsBone metastasesCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[9] 

Other Information

ATC CodeN/A
Related LinksN/A